Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
Study Identifier:
ALXN1720-NEPH-102
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1720
Date
Jun 2022 - May 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 19 - 65 Years
Requirements Information
Sex
Female & Male
Age
19 - 65 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1720
Date
Jun 2022 - May 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 19 - 65 Years years
Requirements Information
Protocol Summary
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
Trial Locations
Location
Status
Location
Clinical Trial Site 2
Anyang-Si, Gyeonggi-do, Republic of Korea, 14068
Status
N/A
Location
Clinical Trial Site 1
Seoul, Republic of Korea, 03080
Status
N/A